Guardant Health's Shield blood test achieves 99% screening adherence in rural clinic study
GH•A study at two rural South Carolina clinics found 99% screening adherence with Guardant Health's Shield blood test. A separate lifetime modeling study projected blood-based screening would avert more colorectal cancer deaths than stool-based tests while increasing colonoscopy use.
1. Studies presented
Guardant Health presented Shield colorectal cancer blood test research at the American College of Gastroenterology's 2026 annual meeting in Nashville. A study at two rural South Carolina clinics found 99% screening adherence, while a separate lifetime modeling study projected blood-based screening would avert more colorectal cancer deaths than stool-based tests and increase colonoscopy use.
